{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:51:41Z","timestamp":1782449501141,"version":"3.54.5"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis and Crohn\u2019s disease are chronic immune-mediated inflammatory diseases affecting distinct barrier organs, yet epidemiological, genetic, transcriptomic, and therapeutic evidence supports partial immune convergence between them. This review argues that the relationship between psoriasis and Crohn\u2019s disease reflects partial immune convergence shaped by tissue context, rather than a single shared disease entity. TNF-\u03b1 and IL-23-centered type 17 immunity represent the most clinically relevant shared upstream programs, whereas downstream effector pathways, especially IL-17-related responses, are shaped differently by skin and gut barrier architecture, resident immune ecology, microbial exposure, and repair demands. We discuss the gut\u2013skin axis with caution: barrier dysfunction, dysbiosis, microbial metabolites, and immune-cell trafficking may connect skin and intestinal inflammation, but direct causal evidence in humans remains limited. TNF inhibitors, IL-12\/23 blockade, and selective IL-23 inhibitors are the most plausible options for selected patients requiring treatment compatible with both skin and gut disease, whereas IL-17 blockade and paradoxical psoriasiform reactions illustrate organ-specific therapeutic tensions. Future progress will depend on patient stratification using clinical phenotypes, biomarkers, tissue profiling, and treatment history to identify patients in whom skin and intestinal inflammation are driven by overlapping immune mechanisms.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1871406","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:40:10Z","timestamp":1782448810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoou","family":"Wang","sequence":"first","affiliation":[{"name":"Yanbian Hospital of Traditional Chinese Medicine, Yanji City Hospital of Traditional Chinese Medicine","place":["Yanji, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitong","family":"Li","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keying","family":"Yu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Wu","sequence":"additional","affiliation":[{"name":"Chengdu Sport University, School of Sports Medicine and Health","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Luo","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0493","article-title":"Crohn\u2019s disease: An update","volume":"23","author":"Cockburn","year":"2023","journal-title":"Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103410","article-title":"Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features","volume":"22","author":"Monteleone","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241227037","article-title":"The association between psoriasis, psoriasis severity, and inflammatory bowel disease: A population-based analysis","volume":"17","author":"Shani","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234535","article-title":"Cutaneous manifestations of inflammatory bowel disease: Basic characteristics, therapy, and potential pathophysiological associations","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000514030","article-title":"Incidence of psoriasis in patients with inflammatory bowel disease: A nationwide population-based matched cohort study","volume":"237","author":"Moon","year":"2021","journal-title":"Dermatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105981","article-title":"Significance of integrated clinical and proteomic characteristics analysis for pathogenesis and management of crohn\u2019s disease with concomitant psoriasis","volume":"121","author":"Zhang","year":"2025","journal-title":"EBioMedicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04459-6","article-title":"Shared genetic architecture between psoriasis and immune-mediated gastrointestinal diseases: A study based on cross-trait GWAS and pleiotropy analysis","volume":"318","author":"Lin","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/s41467-025-56719-8","article-title":"GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets","volume":"16","author":"Dand","year":"2025","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41588-023-01384-0","article-title":"Genetic architecture of the inflammatory bowel diseases across east asian and european ancestries","volume":"55","author":"Liu","year":"2023","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: A roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07723-2","article-title":"Exploration of the shared gene signatures and potential molecular mechanisms between crohn\u2019s disease and psoriasis","volume":"45","author":"Zhang","year":"2026","journal-title":"Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1587705","article-title":"Identification and validation of shared biomarkers and drug repurposing in psoriasis and crohn\u2019s disease: Integrating bioinformatics, machine learning, and experimental approaches","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27020715","article-title":"Spatial imbalance of innate-like T-cell niches underlies clinical trajectories in psoriasis","volume":"27","author":"Bonilha","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq7991","article-title":"Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems","volume":"8","author":"Castillo","year":"2023","journal-title":"Sci Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02225-y","article-title":"Single-cell and spatial transcriptomics of stricturing crohn\u2019s disease highlights a fibrosis-associated network","volume":"57","author":"Kong","year":"2025","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf180","article-title":"Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in postoperative crohn\u2019s disease","volume":"19","author":"Battat","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01994-8","article-title":"A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease","volume":"25","author":"Thomas","year":"2024","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240806","article-title":"Targeting TNF\/TNFR superfamilies in immune-mediated inflammatory diseases","volume":"221","author":"Veerasubramanian","year":"2024","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1424606","article-title":"Anti-TNF\u03b1 in inflammatory bowel disease: From originators to biosimilars","volume":"15","author":"Zeng","year":"2024","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1126247","article-title":"Anti-TNF-\u03b1 therapies for the treatment of crohn\u2019s disease: The past, present and future","volume":"25","author":"Berns","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01218-x","article-title":"Type 17 immunity: Novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells","volume":"21","author":"Ohara","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02183-z","article-title":"Differentiating IL-23 inhibitors in crohn\u2019s disease","volume":"85","author":"Nardone","year":"2025","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00705.x","article-title":"The interleukin-23 axis in intestinal inflammation","volume":"226","author":"Ahern","year":"2008","journal-title":"Immunol Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s10875-010-9368-7","article-title":"Th17 cytokines and the gut mucosal barrier","volume":"30","author":"Blaschitz","year":"2010","journal-title":"J Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2022.07.005","article-title":"The involvement of TH17 cells in the pathogenesis of IBD","volume":"69","author":"Jiang","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393463","article-title":"Anti-IL23\/12 agents and JAK inhibitors for inflammatory bowel disease","volume":"15","author":"Tian","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.06.1280","article-title":"The central roles of keratinocytes in coordinating skin immunity","volume":"144","author":"Simmons","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: A pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2400020","article-title":"Skin-resident T cells contribute to the dynamic disease manifestations of psoriasis","volume":"213","author":"Sortebech","year":"2024","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: From remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12964-024-01984-1","article-title":"Regulation of intestinal tissue-resident memory T cells: A potential target for inflammatory bowel disease","volume":"22","author":"Xia","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41232-024-00334-5","article-title":"Immune cell trafficking: A novel perspective on the gut-skin axis","volume":"44","author":"Zhang","year":"2024","journal-title":"Inflammation Regener"},{"key":"B47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41575-024-00997-y","article-title":"Host-pathobiont interactions in crohn\u2019s disease","volume":"22","author":"Caruso","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: From bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13221","article-title":"Role of IL-22 in homeostasis and diseases of the skin","volume":"130","author":"Lopez","year":"2022","journal-title":"APMIS"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.05.008","article-title":"IL-23 exerts dominant pathogenic functions in crohn\u2019s disease-ileitis","volume":"17","author":"Iliopoulou","year":"2024","journal-title":"Mucosal Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01893-9","article-title":"Colitis induced by IL-17A-inhibitors","volume":"17","author":"Gr\u00fcmme","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1594998","article-title":"Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: A systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40001-025-02295-y","article-title":"Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease","volume":"30","author":"Li","year":"2025","journal-title":"Eur J Med Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2473524","article-title":"The gut-skin axis: A bi-directional, microbiota-driven relationship with therapeutic potential","volume":"17","author":"Jimenez-Sanchez","year":"2025","journal-title":"Gut Microbes"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01183-w","article-title":"Gut microbiota-derived short-chain fatty acids and their role in human health and disease","volume":"23","author":"Mukhopadhya","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41574-025-01107-x","article-title":"Neuro-immuno-endocrinology of the skin: How environment regulates body homeostasis","volume":"21","author":"Slominski","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1427770","article-title":"Editorial: The gut-skin axis: interaction of gut microbiome and skin diseases","volume":"15","author":"Chai","year":"2024","journal-title":"Front Microbiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1038\/s41467-024-47072-3","article-title":"Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice","volume":"15","author":"Dokoshi","year":"2024","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111191","article-title":"Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development","volume":"40","author":"Pinget","year":"2022","journal-title":"Cell Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01225-y","article-title":"TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes in mice","volume":"56","author":"Kim","year":"2024","journal-title":"Exp Mol Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"15405","DOI":"10.1038\/s41598-023-42019-y","article-title":"Regulation of psoriasis, colitis, and the intestinal microbiota by clusterin","volume":"13","author":"Jun","year":"2023","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41392-022-01219-0","article-title":"Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"17495","DOI":"10.1038\/s41598-024-67325-x","article-title":"Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: A metagenomic association analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2203.03022","article-title":"Leaky gut in IBD: Intestinal barrier-gut microbiota interaction","volume":"32","author":"Yu","year":"2022","journal-title":"J Microbiol Biotechnol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00766-3","article-title":"Paracellular permeability and tight junction regulation in gut health and disease","volume":"20","author":"Horowitz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103717","article-title":"Intestinal mucus barrier: A potential therapeutic target for IBD","volume":"24","author":"Qiao","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1159\/000528945","article-title":"Patient perspectives on psoriatic disease burden: Results from the global psoriasis and beyond survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15071","article-title":"Cardiovascular comorbidity in psoriasis - psoriatic inflammation is more than just skin deep","volume":"21","author":"Kommoss","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2292239","article-title":"Heterogeneous associations of gut microbiota with crohn\u2019s disease activity","volume":"16","author":"Pinto","year":"2024","journal-title":"Gut Microbes"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i1.102042","article-title":"Creeping fat and gut microbiota in crohn\u2019s disease","volume":"31","author":"Quaglio","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083998","article-title":"Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis","volume":"22","author":"Olejniczak-Staruch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177521","article-title":"Alterations of gut microbiota for the onset and treatment of psoriasis: A systematic review","volume":"998","author":"Xue","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118655","article-title":"Current perspectives on the human skin microbiome: Functional insights and strategies for therapeutic modulation","volume":"193","author":"Suri","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01211-9","article-title":"The human skin microbiome: From metagenomes to therapeutics","volume":"23","author":"Oh","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12866-025-04395-5","article-title":"Integrated microbiome and metabolome analysis reveals microbial-metabolic interactions in psoriasis pathogenesis","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Microbiol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-024-01057-x","article-title":"How bile acids and the microbiota interact to shape host immunity","volume":"24","author":"Lee","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128280","article-title":"Tryptophan metabolism and the intestinal microbiota: Implications for inflammatory bowel disease","volume":"300","author":"Hua","year":"2025","journal-title":"Microbiol Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf042","article-title":"Environmental risk factors of inflammatory bowel disease: Toward a strategy of preventative health","volume":"19","author":"Chhibba","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2024.1395269","article-title":"The effect of smoking in inflammatory bowel disease outcomes","volume":"3","author":"Alzahrani","year":"2024","journal-title":"Front Gastroenterol (Lausanne)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity-inflammation axis in psoriatic disease: Mechanisms and therapeutic strategies","volume":"22","author":"Haberman","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00933-y","article-title":"Antibiotic perturbations to the gut microbiome","volume":"21","author":"Fishbein","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2023.10.014","article-title":"Stressed to the core: Inflammation and intestinal permeability link stress-related gut microbiota shifts to mental health outcomes","volume":"95","author":"Madison","year":"2024","journal-title":"Biol Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136955","article-title":"Roles of infection in psoriasis","volume":"23","author":"Zhou","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100249","article-title":"Quantitative aggregation of microbiome sequencing data provides insights into the associations between the skin microbiome and psoriasis","volume":"4","author":"Chan","year":"2024","journal-title":"JID Innov"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.09.014","article-title":"The gut microbiome at the onset of inflammatory bowel disease: A systematic review and unified bioinformatic synthesis","volume":"170","author":"Peter","year":"2026","journal-title":"Gastroenterology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"98","DOI":"10.15403\/jgld-5729","article-title":"The efficacy of traditional Chinese medicine for crohn\u2019s disease treatment: A systematic review and meta-analysis","volume":"34","author":"Chang","year":"2025","journal-title":"J Gastrointestin Liver Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6710451","article-title":"Adjuvant treatment of crohn\u2019s disease with traditional Chinese medicine: A meta-analysis","volume":"2019","author":"Wang","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101300","article-title":"Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate crohn\u2019s disease: A randomized controlled trial","volume":"45","author":"Bao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i31.11000","article-title":"Randomized controlled trial: Moxibustion and acupuncture for the treatment of crohn\u2019s disease","volume":"20","author":"Bao","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i16.4986","article-title":"Moxibustion combined with acupuncture increases tight junction protein expression in crohn\u2019s disease patients","volume":"21","author":"Shang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.599433","article-title":"Chinese herbal medicine for psoriasis: Evidence from 11 high-quality randomized controlled trials","volume":"11","author":"Luo","year":"2020","journal-title":"Front Pharmacol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/09546634.2016.1178377","article-title":"Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review","volume":"28","author":"Parker","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1789048","article-title":"Evidence and potential mechanisms of traditional Chinese medicine for the treatment of psoriasis vulgaris: A systematic review and meta-analysis","volume":"33","author":"Dai","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: An updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: Systematic review with meta-analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: The IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials","volume":"82","author":"Reich","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2519525","article-title":"Biologics targeting IL-23 in moderate-to-severe psoriasis: Lessons learned from real-world use","volume":"25","author":"Megna","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: Does it clinically matter","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf080","article-title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"D\u2019Haens","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00928-w","article-title":"Next-generation anti-IL-17 agents for psoriatic disease: A pipeline review","volume":"26","author":"Kim","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100211","article-title":"Paradoxical psoriasis: The flip side of idiopathic psoriasis or an autocephalous reversible drug reaction","volume":"7","author":"Lu","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241299564","article-title":"Psoriasis and inflammatory bowel disease: Concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12\/23 and anti-IL-23 antibodies","volume":"17","author":"Bezzio","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09752-6","article-title":"Impact of comorbid psoriasis on the efficacy of ustekinumab and mirikizumab in inflammatory bowel disease: A post-hoc analysis of UNITI, SEAVUE, and LUCENT","author":"Wong","year":"2026","journal-title":"Dig Dis Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.09.038","article-title":"AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn\u2019s disease","volume":"169","author":"Scott","year":"2025","journal-title":"Gastroenterology"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2025-103327","article-title":"Inflammatory bowel disease\u2013dermatology: Evaluation of a collaborative, multidisciplinary, patient-centred care model","author":"Hussain","year":"2025","journal-title":"Frontline Gastroenterol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3748\/wjg.v30.i1.50","article-title":"Treat to target in Crohn\u2019s disease: A practical guide for clinicians","volume":"30","author":"Srinivasan","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1316-y","article-title":"Topical herbal medicine combined with pharmacotherapy for psoriasis: A systematic review and meta-analysis","volume":"305","author":"Deng","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-2386","article-title":"A systematic review and meta-analysis on the efficacy and safety of traditional Chinese medicine bath in the treatment of psoriasis vulgaris","volume":"10","author":"Lei","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00069","article-title":"An overview of the evidence and mechanisms of herb-drug interactions","volume":"3","author":"Fasinu","year":"2012","journal-title":"Front Pharmacol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04066-2","article-title":"Advancing herbal medicine safety: The need for a global pharmacovigilance approach","volume":"398","author":"Sethi","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf144","article-title":"Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: How to choose between them and why it matters","volume":"19","author":"Pugliano","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S543289","article-title":"Multidisciplinary management of psoriasis: Integrating diet, exercise, psychological support, and sleep interventions","volume":"18","author":"Dymek","year":"2025","journal-title":"Clinical Cosmetic Investigational Dermatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/nu16162597","article-title":"Nutritional management for Crohn\u2019s disease","volume":"16","author":"Sila","year":"2024","journal-title":"Nutrients"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2022-0049","article-title":"Effectiveness of smoking cessation interventions for smokers with Crohn\u2019s disease: A systematic review","volume":"9","author":"Nasr","year":"2023","journal-title":"Future Sci OA"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/s12529-024-10315-0","article-title":"Effect of psychological intervention on quality of life among patients with psoriasis: A meta-analysis","volume":"31","author":"Wei","year":"2024","journal-title":"Int J Behav Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s13555-026-01664-7","article-title":"Management of obesity in psoriasis consultations","volume":"16","author":"Nicolau","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102334","article-title":"Psoriasis as a potential risk factor for inflammatory bowel disease: Findings from a nationally representative Korean population","volume":"13","author":"Kang","year":"2025","journal-title":"Biomedicines"},{"key":"B135","doi-asserted-by":"publisher","first-page":"20526","DOI":"10.1038\/s41598-022-24872-5","article-title":"The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases","volume":"12","author":"Sun","year":"2022","journal-title":"Sci Rep"},{"key":"B136","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of systemic treatment response in people with psoriasis: A scoping review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br J Dermatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12720","article-title":"Multi-omics biomarkers for predicting efficacy of biologic and small-molecule therapies in adults with inflammatory bowel disease: A systematic review","volume":"13","author":"Chen","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"B138","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10238-025-01731-x","article-title":"Dual-targeted therapy for the management of refractory Crohn\u2019s disease: A retrospective cohort study","volume":"25","author":"He","year":"2025","journal-title":"Clin Exp Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.surge.2025.03.002","article-title":"Multi-disciplinary teams for Crohn\u2019s disease: Who should be presented","volume":"23","author":"Derbyshire","year":"2025","journal-title":"Surgeon: J R Colleges Surgeons Edinburgh Ireland"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103853","article-title":"Clinical features, pathogenesis, and treatment of inflammatory bowel disease-associated spondyloarthritis","volume":"24","author":"Akiyama","year":"2025","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1871406\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:40:14Z","timestamp":1782448814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1871406\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":140,"alternative-id":["10.3389\/fimmu.2026.1871406"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1871406","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1871406"}}